Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MIP-DILI

Financiado

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Inju...

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both... ver más

31/03/2017

ASTRAZENECA AB

32M€

Presupuesto del proyecto: 32M€

Líder del proyecto

ASTRAZENECA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 21 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2017-03-31

0% 100%

21 Participantes

ASTRAZENECA AB

Lider

ABBV

N.D. | Participante

ULEI

N.D. | Participante

GSK

N.D. | Participante

Proyectos interesantes

PID2019-106000RB-C22 MODELOS INNOVADORES DE CELULAS HEPATICAS HUMANAS EN 3D PARA... 157K€ Cerrado

CPP2021-008633 Modelos 3D innovadores derivados de tejido hepático humano p... 395K€ Cerrado

PCI2024-153519 Herramientas diagnósticas, pronósticas y terapéuticas 135K€ Cerrado

SPHERO-NASH A novel NASH model for target and drug candidate identificat... 150K€ Cerrado

PCI2024-153423 Herramientas diagnósticas, pronósticas y terapéuticas 315K€ Cerrado

SAF2016-78756-P MODELOS IN VITRO DE EVALUACION BIOFARMACEUTICA: BARRERAS BIO... 85K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 61 meses Fecha Inicio: 2012-02-01
Fecha Fin: 2017-03-31

Líder del proyecto

ASTRAZENECA AB

TRL 4-5

Presupuesto del proyecto 32M€

Descripción del proyecto The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test systems, bioanalysis and systems analysis will be adopted to evaluate existing models and develop new models that can provide validated test systems with respect to the prediction of specific forms of DILI and further elucidation of mechanisms. The approach will encompass completely characterised cell lines, well-defined and physiologically stable hepatocytes, multi-cell type in vitro models including novel bioreactors, animal models and appropriate ex vivo human cell models. A systematic analysis of data and iteration at each stage will select the ‘best’ cell line, animal model or pathway for further investigation moving from simple systems to more complex models with reference to relevant clinical and preclinical data on the various forms of DILI. Triangulation of human, in vitro and animal data will provide a fundamental understanding of how drugs can harm the liver. It will then be possible to define the application of each particular novel test system in the context of drug development, and its use in the prediction of liabilities associated with the various forms of DILI that occur in man. Just as importantly, the project will define those models that are not appropriate as decision-making tools for the prediction of DILI in man.The MIP-DILI consortium contains Key Opinion Leaders from academia, the biotechnology sector and the pharmaceutical industry in the fields of drug development, drug metabolism, drug toxicology, drug hypersensitivity, liver immunology, liver cell biology, pharmacogenetics, systems biology and clinical adverse drug reactions.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores